Ratings SSY Group Limited

Equities

2005

KYG8406X1034

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
4.71 ^HKD	+0.64%		-4.66%	-4.66%

Apr. 16	SSY Group Logs Nearly 15% Boost in Q1 Profit	MT
Apr. 08	SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	MT

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
With a P/E ratio at 10.64 for the current year and 8.93 for next year, earnings multiples are highly attractive compared with competitors.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SSY GROUP LIMITED	-4.66%	1.77B	B-
ELI LILLY AND COMPANY	+24.60%	672B	C+
NOVO NORDISK A/S	+24.08%	550B	B
JOHNSON & JOHNSON	-5.63%	351B	C+
MERCK & CO., INC.	+15.37%	317B	B-
ABBVIE INC.	+7.38%	292B	C+
ASTRAZENECA PLC	+3.26%	211B	B+
NOVARTIS AG	+0.78%	203B	B-
PFIZER, INC.	-9.69%	144B	C+
AMGEN INC.	-6.63%	141B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes